BioNTech CEO: Pfizer coronavirus vaccine could protect from infection for one year
BioNTech co-founder and CEO Dr. Ugur Sahin provides insight into the vaccine progress with Pfizer.
The Pfizer-BioNTech coronavirus vaccine could protect patients from the virus for a year, BioNTech CEO Ugur Sahin told "Mornings with Maria" on Thursday.
Continue Reading Below
BEHIND PFIZER'S VACCINE, AN UNDERSTATED HUSBAND-AND-WIFE DREAM TEAM
"There’s a good chance that the vaccine not only is protective but could protect from infection or reinfection for a significant period of time," Sahin said. "I personally expect that a vaccine could protect us … for at least one year. If we learn that we need to reimmunize, we could do that after one year."
Pfizer and BioNTech's vaccine was found to be more than 90% effective in preventing coronavirus in their Phase 3 clinical trial.
"This is indeed unprecedented," Sahin said. "We started vaccine candidates development end of January, about 10 months ago in Germany, by starting to evaluate more than 20 candidates. In March, we announced our partnership with Pfizer."